Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/28/20
End: 12/12/20
Due: 12/12/21
Phase: N/A
Priority: Normal
Start: 09/17/21
End: 11/18/22
Due: 11/18/23
Phase: N/A
Priority: Normal
Start: 04/13/23
End: 12/19/23
Due: 12/19/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects | NCT05468060 | Zhejiang Palo Alto Pharmaceuticals, Inc. | user2@example.com | None | 2020-06-28 | 2020-12-12 | 2021-12-12 | - | - | 2025-07-14 |
| Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients | NCT05019040 | Zhejiang Palo Alto Pharmaceuticals, Inc. | user2@example.com | None | 2021-09-17 | 2022-11-18 | 2023-11-18 | - | - | 2025-07-14 |
| Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects | NCT05851261 | Zhejiang Palo Alto Pharmaceuticals, Inc. | user2@example.com | None | 2023-04-13 | 2023-12-19 | 2024-12-19 | - | - | 2025-07-14 |